Hepalink

Shenzhen Hepalink Pharmaceutical Group Co., Ltd., founded in 1998, is a significant player in the global pharmaceutical and healthcare industries. Operating from Shenzhen, China, the company has established a broad international footprint, serving markets across Hong Kong, the United States, Europe, and Mainland China. Hepalink's strategic focus encompasses a diverse range of pharmaceutical activities, positioning it as a key entity within the biopharmaceutical sector. Its operations are structured across four primary segments: Finished Dose Pharmaceutical Products, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization (CDMO), and Other ventures.

The company's product portfolio is robust, featuring critical offerings such as enoxaparin sodium injection and various API products, including heparin sodium API and enoxaparin sodium API. Beyond manufacturing, Hepalink is deeply invested in research and development, contributing to advancements in recombinant pharmaceutical products, critical non-viral vectors, and intermediates for gene therapy. The company also engages in the development and manufacture of naturally derived pharmaceutical products. To understand the driving force behind these innovations, one can Meet Hepalink's team and learn about their expertise.

With a substantial revenue of $774.7M and an employee range of 1,000 - 5,000 individuals, Hepalink demonstrates significant operational scale. Its business model extends beyond core pharmaceutical production to include property management, investment management and consulting, biopharmaceutical technology development, and equity and venture investment activities. This diversified approach, coupled with its commitment to producing essential heparin-based products and other biopharmaceuticals, solidifies Hepalink's position in the competitive healthcare landscape.